BR112018075434A2 - anticorpo isolado ou fragmento de ligação de antígeno do mesmo, composição farmacêutica, e, métodos para tratar câncer e para modular resposta imune antitumor. - Google Patents

anticorpo isolado ou fragmento de ligação de antígeno do mesmo, composição farmacêutica, e, métodos para tratar câncer e para modular resposta imune antitumor.

Info

Publication number
BR112018075434A2
BR112018075434A2 BR112018075434-0A BR112018075434A BR112018075434A2 BR 112018075434 A2 BR112018075434 A2 BR 112018075434A2 BR 112018075434 A BR112018075434 A BR 112018075434A BR 112018075434 A2 BR112018075434 A2 BR 112018075434A2
Authority
BR
Brazil
Prior art keywords
methods
antigen binding
modulating
pharmaceutical composition
immune response
Prior art date
Application number
BR112018075434-0A
Other languages
English (en)
Inventor
Delfino Frank
Skokos Dimitris
Wang Bei
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of BR112018075434A2 publication Critical patent/BR112018075434A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

são aqui fornecidos anticorpos, e fragmentos de ligação de antígeno dos mesmos que especificamente liga o receptor do fator de necrose de tumor induzido por glicocorticóide (gitr) e métodos de usar os mesmos, incluindo, por exemplo, métodos de tratamento usando os mesmos.
BR112018075434-0A 2016-06-10 2017-06-09 anticorpo isolado ou fragmento de ligação de antígeno do mesmo, composição farmacêutica, e, métodos para tratar câncer e para modular resposta imune antitumor. BR112018075434A2 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662348353P 2016-06-10 2016-06-10
US62/348353 2016-06-10
US201662432023P 2016-12-09 2016-12-09
US62/432023 2016-12-09
US201762500312P 2017-05-02 2017-05-02
US62/500312 2017-05-02
PCT/US2017/036818 WO2017214548A1 (en) 2016-06-10 2017-06-09 Anti-gitr antibodies and uses thereof

Publications (1)

Publication Number Publication Date
BR112018075434A2 true BR112018075434A2 (pt) 2019-03-19

Family

ID=59078260

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018075434-0A BR112018075434A2 (pt) 2016-06-10 2017-06-09 anticorpo isolado ou fragmento de ligação de antígeno do mesmo, composição farmacêutica, e, métodos para tratar câncer e para modular resposta imune antitumor.

Country Status (18)

Country Link
US (3) US10738126B2 (pt)
EP (2) EP4344748A3 (pt)
JP (2) JP7162535B2 (pt)
KR (1) KR102495601B1 (pt)
CN (1) CN109563170B (pt)
AU (1) AU2017278193B9 (pt)
BR (1) BR112018075434A2 (pt)
CA (1) CA3027121A1 (pt)
CL (1) CL2018003515A1 (pt)
CO (1) CO2018013298A2 (pt)
IL (1) IL263273A (pt)
MA (1) MA45233A (pt)
MX (2) MX2018015350A (pt)
MY (1) MY200162A (pt)
PH (1) PH12018502502A1 (pt)
SG (1) SG11201810525XA (pt)
WO (1) WO2017214548A1 (pt)
ZA (1) ZA201807920B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR097306A1 (es) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
MA45233A (fr) 2016-06-10 2019-04-17 Regeneron Pharma Anticorps anti-gitr et leurs utilisations
KR20230133934A (ko) 2016-10-11 2023-09-19 아게누스 인코포레이티드 항-lag-3 항체 및 이의 사용 방법
WO2018107178A1 (en) 2016-12-09 2018-06-14 Regeneron Pharmaceuticals, Inc. Systems and methods for sequencing t cell receptors and uses thereof
US11873341B2 (en) * 2018-03-13 2024-01-16 Tusk Therapeutics Ltd. Anti-CD25 for tumour specific cell depletion
US20220153819A1 (en) 2019-02-12 2022-05-19 Regeneron Pharmaceuticals, Inc. Compositions and methods for using bispecific antibodies to bind complement and a target antigen
RU2734432C1 (ru) 2019-04-23 2020-10-16 Закрытое Акционерное Общество "Биокад" Моноклональное антитело, которое специфически связывается с GITR
EP4085074A4 (en) * 2020-01-02 2024-05-15 Nanjing GenScript Biotech Co., Ltd. ANTI-GITR ANTIBODIES AND THEIR USES
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
CN115244084A (zh) 2020-03-06 2022-10-25 瑞泽恩制药公司 抗gitr抗体及其用途
CN116761622A (zh) * 2021-01-08 2023-09-15 苏州丁孚靶点生物技术有限公司 药物产品及其用途
TW202237642A (zh) * 2021-01-08 2022-10-01 美商１０Ｘ基因組學有限公司 對冠狀病毒具有特異性的抗原結合多肽及其用途
WO2023175614A1 (en) 2022-03-15 2023-09-21 Yeda Research And Development Co. Ltd. Anti glucocorticoid-induced tnfr-related (gitr) protein antibodies and uses thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US6111090A (en) 1996-08-16 2000-08-29 Schering Corporation Mammalian cell surface antigens; related reagents
DE69738749D1 (de) 1996-08-16 2008-07-17 Schering Corp Zelloberflächen-antigen aus säugetieren und verwandte reagenzien
US6503184B1 (en) 1997-10-21 2003-01-07 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
US6689607B2 (en) 1997-10-21 2004-02-10 Human Genome Sciences, Inc. Human tumor, necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
EP1032672B1 (en) 1997-11-18 2008-12-31 Genentech, Inc. Dna19355 polypeptide, a tumor necrosis factor homolog
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
EP1462114A1 (en) 2003-03-28 2004-09-29 Universiteit Utrecht Holding B.V. Methods and means to suppress symptons of an allergic disease by inhibiting the glucocorticoid-induced tumor necrosis factor receptor (GRIT or TNFRSF18)
EP1631588A2 (en) 2003-05-23 2006-03-08 Wyeth Gitr ligand and gitr ligand-related molecules and antibodies and uses thereof
US20060099171A1 (en) 2004-11-05 2006-05-11 Masahide Tone Mouse glucocorticoid-induced TNF receptor ligand is costimulatory for T cells
DK2343320T3 (da) 2005-03-25 2018-01-29 Gitr Inc Anti-gitr-antistoffer og anvendelser deraf
US20110212086A1 (en) 2006-01-19 2011-09-01 Genzyme Corporation GITR Antibodies For The Treatment of Cancer
WO2007084775A2 (en) 2006-01-20 2007-07-26 The Trustees Of The University Of Pennsylvania Compositions and methods for modulation of suppressor t cell activation
MX2008014804A (es) 2006-06-02 2009-01-27 Regeneron Pharma Anticuerpos de afinidad elevada a receptor de il-6 humano.
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
EP2175884B8 (en) 2007-07-12 2017-02-22 GITR, Inc. Combination therapies employing gitr binding molecules
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
LT3023438T (lt) 2009-09-03 2020-05-11 Merck Sharp & Dohme Corp. Anti-gitr antikūnai
WO2013039954A1 (en) 2011-09-14 2013-03-21 Sanofi Anti-gitr antibodies
US9175308B2 (en) 2011-10-07 2015-11-03 Mie University Chimeric antigen receptor
KR101566539B1 (ko) 2012-06-08 2015-11-05 국립암센터 신규한 Ｔｈ2 세포 전환용 에피토프 및 이의 용도
AR097306A1 (es) * 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
KR102433464B1 (ko) 2014-05-28 2022-08-17 아게누스 인코포레이티드 항-gitr 항체 및 이의 사용 방법
SG10201810507WA (en) 2014-06-06 2018-12-28 Bristol Myers Squibb Co Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
CN107250159A (zh) 2014-10-03 2017-10-13 达纳－法伯癌症研究所公司 糖皮质激素诱导的肿瘤坏死因子受体(gitr)抗体及其使用方法
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
JP6827415B2 (ja) * 2014-10-31 2021-02-10 メレオ バイオファーマ ５ インコーポレイテッド 疾患の処置のための併用療法
MA45233A (fr) 2016-06-10 2019-04-17 Regeneron Pharma Anticorps anti-gitr et leurs utilisations

Also Published As

Publication number Publication date
US11414494B2 (en) 2022-08-16
CL2018003515A1 (es) 2019-03-08
PH12018502502A1 (en) 2019-04-08
US20230042324A1 (en) 2023-02-09
MY200162A (en) 2023-12-09
WO2017214548A1 (en) 2017-12-14
AU2017278193A1 (en) 2018-12-13
MX2018015350A (es) 2019-08-26
CO2018013298A2 (es) 2019-02-19
AU2017278193B9 (en) 2024-02-01
KR20190020297A (ko) 2019-02-28
SG11201810525XA (en) 2018-12-28
US10738126B2 (en) 2020-08-11
AU2017278193B2 (en) 2024-01-18
EP4344748A3 (en) 2024-06-12
IL263273A (en) 2018-12-31
JP2019521098A (ja) 2019-07-25
JP7162535B2 (ja) 2022-10-28
EP4344748A2 (en) 2024-04-03
MA45233A (fr) 2019-04-17
CA3027121A1 (en) 2017-12-14
CN109563170B (zh) 2023-10-13
MX2022014695A (es) 2022-12-16
KR102495601B1 (ko) 2023-02-06
JP2022159476A (ja) 2022-10-17
US20210147565A1 (en) 2021-05-20
EP3468999A1 (en) 2019-04-17
US20170355774A1 (en) 2017-12-14
ZA201807920B (en) 2024-01-31
CN109563170A (zh) 2019-04-02
EP3468999B1 (en) 2024-01-10

Similar Documents

Publication Publication Date Title
BR112018075434A2 (pt) anticorpo isolado ou fragmento de ligação de antígeno do mesmo, composição farmacêutica, e, métodos para tratar câncer e para modular resposta imune antitumor.
PH12019500270A1 (en) Combination therapy for cancer
CY1124791T1 (el) Μορια δεσμευσης ειδικα για cd73 και χρησεις αυτων
PH12016501549A1 (en) Tergeted tgf� inhibition
ZA202005259B (en) Anti-ctla4 antibodies and methods of making and using the same
BR112018007046A2 (pt) anticorpo isolado ou fragmento de ligação a antígeno, composição farmacêutica, molécula de polinucleotídeo isolado, vetor, célula, e, métodos para inibir o crescimento de um tumor ou de uma célula tumoral e para tratar uma doença ou distúrbio.
MX2020012905A (es) Proteínas de unión multiespecíficas y mejoras con estas.
AR105444A1 (es) Anticuerpos terapéuticos que se unen a la proteína codificada por el gen de activación de linfocitos 3 (lag3)
BR112016016207A2 (pt) Anticorpo anti-pd-l1 isolado ou fragmento de ligação ao antígeno do mesmo, seu método de produção, composição farmacêutica, molécula de polinucleotídeo isolada, vetor, célula, e uso dos mesmos
BR112016028378A2 (pt) anticorpos contra o receptor do fator de necrose tumoral induzido por glicocorticoide (gitr) e usos dos mesmos
BR112016030686A2 (pt) anticorpos anti tau humanizados
UY36536A (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
CL2019002144A1 (es) Conjugados de fármacos y anticuerpos anti–ccr7.
BR112018002451A2 (pt) estruturas de ligação com antígeno para moléculas alvo
BR112016009797A2 (pt) anticorpos específicos de ligante 1a do tipo fator de necrose tumoral e composições e usos dos mesmos
BR112019010595A2 (pt) anticorpo ou fragmento de ligação ao antígeno do mesmo, combinação de moléculas de ácido nucleico isoladas, composição farmacêutica, kit, e, método para selecionar um composto.
CY1123781T1 (el) Anti-tnf αλφα-αντισωματα και λειτουργικα θραυσματα αυτων
TN2017000173A1 (en) Antibody drug conjugates
BR112019005129A2 (pt) anticorpos anti-pd-1
CY1123784T1 (el) Αντισωματα enanti-tnf αλφα και λειτουργικα θραυσματα αυτων
BR112018072118A2 (pt) anticorpos de interferona beta e usos dos mesmos
BR112017021484A2 (pt) anticorpos de direcionamento à proteína morfogenética óssea 9 (bmp9) e métodos para os mesmos
BR112021016791A2 (pt) Proteínas de ligação de antígenos que se ligam a bcma
BR112021026309A2 (pt) Anticorpos para ativação de células t
EA201892090A1 (ru) АНТИТЕЛА К ФНО-α И ИХ ФУНКЦИОНАЛЬНЫЕ ФРАГМЕНТЫ

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]